MRI proton density fat fraction
1 paper1 finding
- Human trial1
Interventions
1TLC-6740
downin humans1
1 study
TLC-6740
downin humans1
TLC-6740 decreases MRI proton density fat fraction in humans (-60.6% vs -44.0% (p=0.12)).
“Among participants with BL liver fat ≥5% (MASLD), MRI-PDFF decreased -60.6% with TLC-6740 (n=13) vs -44.0% with placebo (n=7; p=0.12).”
Human trialcombination with tirzepatide in adults with obesity and baseline liver fat >=5%180 mg daily oral24 weeks
ADA Scientific Sessions 2026 abstract5 Jun 2026
Latest
2 in 12 monthsADA Scientific Sessions 2026 Abstract
Increasing Energy Expenditure with the Liver-Targeted Mitochondrial Protonophore TLC-6740 Enhances Weight Loss and Metabolic Benefits in Combination with Tirzepatide in Obesity: A Phase 2a Study
Randomised trial in 55 peopleTirzepatide
AHA Scientific Sessions 2025 Abstract
Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study
Randomised trial in 48 peopleObesity
Journal of Hepatology
Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease
Trial in peopleInterventions